Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Study: Lower hospitalization rates for St. Jude Medical’s CardioMEMS heart failure monitor
St. Jude Medical put another brick in the wall of its defense of the CardioMEMS heart failure monitor, which was assailed earlier this year by claims that the device is not cost-effective, as new data from the 550-patient Champion trial showed lower hospitalization rates for patients treating using data from the CardioMEMS device.
Sign up to get our free newsletters delivered straight to your inbox
2. House bill would ban Bayer’s Essure
A bill introduced by Rep. Mike Fitzpatrick (R-Pa.) would ban U.S. sales of the Essure female sterilization implant made by Bayer. The “E-Free Act,” introduced Nov. 4, would direct the FDA commissioner to withdraw approval for the Essure device, the only approved permanent birth control device in the U.S.
Read more
1. Jury clears Zimmer Biomet in 1st NexGen Flex knee implant trial
An Illinois jury last week cleared Zimmer Biomet in the 1st bellwether trial of the more than 900 lawsuits lodged over its NexGen Flex knee replacements.
Plaintiff Kathy Batty alleged that the double knee replacements she had in 2009 using the NexGen Flex implants failed, requiring revision surgeries after 2 years. But the jury in the U.S. District Court for Northern Illinois found that Batty failed to prove her defective design and failure to warn claims.
